ALMR
NASDAQAlamar Biosciences Inc.
Alamar Biosciences Inc. (ALMR) is a Biotechnology: Laboratory Analytical Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 20 wire items for ALMR, including 8 insider trades, 6 SEC filings and 5 press releases and news items. The most recent was published Nov 14, 2026.
ALMR rankings
News · 26 weeks42+129%
2026-05-172026-11-08
Mix2990d
- Insider12(41%)
- SEC Filings7(24%)
- Other7(24%)
- Earnings2(7%)
- Leadership1(3%)
Activity · 52 weeks6835 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $2,941,571 worth of shares (100,117 units at $29.38) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $3,327,146 worth of shares (111,313 units at $29.89) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- PRAlamar Biosciences to Participate in Upcoming Investor ConferencesFremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL Fireside chat on Tuesday, November 10 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Citi’s 2026 Global Healthcare Conference in Miami, FL Investor meetings on Wednesday, December 2 Interested parties may access a live and archived webcast of the session on the "Investors" section of the company website at investors.alamarbio.com. A
- SECSEC Form 10-Q filed by Alamar Biosciences Inc.10-Q - Alamar Biosciences, Inc. (0002104204) (Filer)
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $5,676,413 worth of shares (187,636 units at $30.25) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- SECAlamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Alamar Biosciences, Inc. (0002104204) (Filer)
- PRAlamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026. Recent Highlights Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025Selected by UK Biobank to profile 80,000 samples for study targeting earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditionsLaunched a strategic scientific collaboration with GSK for large-scale 60,000-sample stud
- PRAlamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision MedicineFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE:GSK) that will use Alamar’s NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. The collaboration intends to generate deep proteomic insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings. Many d
- PRUPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease StudyFREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX:NHLTY, NGHLF) today announced the launch of the UK Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disease. The UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study will be conducted in Nightingale’s laboratories using Alamar’s NULISA platform, which is purpose-built to detect low-abundance proteins at a sensitivity not previously achievable at scale, and will measure hundreds of circulating protein biomar
- PRAlamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease StudyFREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX:NHLTY, NGHLF) today announced the launch of the UK Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disease. The UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study will be conducted in Nightingale’s laboratories using Alamar’s NULISA platform, which is purpose-built to detect low-abundance proteins at a sensitivity not previously achievable at scale, and will measure hundreds of circulating protein biomar
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $5,968,888 worth of shares (185,731 units at $32.14) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- PREmory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar TechnologyFremont, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced researchers at Emory University have identified a 10-protein blood signature that distinguished patients with amyotrophic lateral sclerosis (ALS) from healthy controls with 98.3% balanced accuracy in an independent validation cohort. The study, published in Nature Communications, used Alamar Biosciences’ NULISA™ technology to measure more than 300 neurological and inflammatory proteins in each blood sample. ALS can be difficult to diagnose, particularly early in the disease or when symptoms r
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $8,569,760 worth of shares (280,458 units at $30.56) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $10,253,095 worth of shares (342,626 units at $29.93) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $5,949,983 worth of shares (217,512 units at $27.35) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERLarge owner Qiming Corporate Gp Vi, Ltd. sold $4,816,121 worth of shares (173,673 units at $27.73) (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- SECSEC Form 144 filed by Alamar Biosciences Inc.144 - Alamar Biosciences, Inc. (0002104204) (Subject)
- SECSEC Form 144 filed by Alamar Biosciences Inc.144 - Alamar Biosciences, Inc. (0002104204) (Subject)
- SECSEC Form 144 filed by Alamar Biosciences Inc.144 - Alamar Biosciences, Inc. (0002104204) (Subject)
- SECSEC Form 144 filed by Alamar Biosciences Inc.144 - Alamar Biosciences, Inc. (0002104204) (Subject)
- PRAlamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on Tuesday, November 3, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event. About Alamar Biosciences, Inc.Alamar is a commercial-stage proteomics compan
- PRAlamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership TeamFREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the appointment of Bob Ragusa to its board of directors. Mr. Ragusa brings more than two decades of leadership across genomics, diagnostics and biotech. Most recently, he served as CEO of GRAIL, the pioneering multi-cancer early detection company, and previously as chief operations officer of Illumina. "I am thrilled to join the Alamar team at such an exciting moment for the company," said Bob Ragusa. "Throughout my career, I have seen how the right technology can change what is possible in medic
- PRLancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s TreatmentFREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab. Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar’s NULISAseq™ CNS 120 panel to mea
- INSIDERGeneral Counsel Brottem John L. was granted 29,000 shares (SEC Form 4)4 - Alamar Biosciences, Inc. (0002104204) (Issuer)
- INSIDERSEC Form 3 filed by new insider Brottem John L.3 - Alamar Biosciences, Inc. (0002104204) (Issuer)
ALMR FAQ
7 questionsWhat is the latest news on ALMR?
In the last 30 days Quantisnow tracked 20 wire items for ALMR: 8 insider trades, 6 SEC filings, 5 press releases and news items and 1 earnings update. The most recent was published on November 14, 2026.Where does ALMR stock trade?
Alamar Biosciences Inc. (ALMR) is listed on NASDAQ.What sector and industry is ALMR in?
Alamar Biosciences Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Alamar Biosciences Inc. go public?
Alamar Biosciences Inc. (ALMR) completed its IPO in 2026.What are analysts saying about ALMR?
Alamar Biosciences Inc. has had 5 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $30.00 price target on 2026-05-12. Recent price targets range from $27.00 to $35.00.What companies are similar to ALMR?
Notable peers in the same industry include RVTY (Revvity Inc.), WAT (Waters Corporation), TXG (10x Genomics Inc.), A (Agilent Technologies Inc.), MTD (Mettler-Toledo International Inc.). Compare ALMR side-by-side with any of them on Quantisnow.How can I track ALMR on Quantisnow?
Quantisnow aggregates Alamar Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALMR to receive live email and push alerts on every new disclosure.